Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Total Debt
Short-term and long-term borrowings combined.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 37.8% from a year ago
Total debt stood at $10.8M at the end of Q1 FY2026, up 37.8% from a year earlier and down 5.9% from the prior quarter. Over 3 fiscal years it compounded at +3.2% a year.
Context
- Total debt amounted to 2.2% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +37.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 11.48M USD
- Year-over-year change
- +678.0%
- 3-year CAGR
- +3.2%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.48M | +678.0% |
| FY2024 | 2024-12-31 | 1.48M | -31.2% |
| FY2023 | 2023-12-31 | 2.15M | -79.4% |
| FY2022 | 2022-12-31 | 10.44M | — |
Total Debt vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 total debt of $10.8M is the 3rd highest of the 10 companies compared; the peer median is $5.59M.
- Its year-over-year change of +37.8% is the 2nd highest of 10, against a peer median of -7.7%.
- Total debt amounts to 2.2% of total assets for RAPP, versus a peer median of 1.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $219.21M | +0.9% | +36.6% | 28.8% | |
| Sep 2026 | $57.32M | +4.6% | -5.6% | 3.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $10.8M | +37.8% | +3.2% | 2.2% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $6.95M | +15.9% | +12.1% | 2.7% |
| Mar 2026 | $5.69M | -78.5% | -62.3% | 2.1% | |
| Mar 2026 | $5.59M | -12.6% | -2.6% | 1.3% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $3.47M | -7.7% | -47.1% | 0.9% |
| Sep 2026 | $732K | +67.9% | -68.4% | 0.1% | |
| Mar 2026 | $465K | -26.8% | -24.4% | 1.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $410K | -56.3% | -61.6% | 0.3% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $5.59M | -7.7% | -24.4% | 1.3% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.